Antares Pharma Target of Unusually High Options Trading (ATRS)
Antares Pharma (NASDAQ:ATRS) saw some unusual options trading activity on Monday. Stock investors purchased 7,234 call options on the stock, Analyst Ratings Network reports. This is an increase of 248% compared to the typical daily volume of 2,078 call options.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Antares Pharma in a research note to investors on Tuesday, October 8th. They now have a $6.00 price target on the stock, up previously from $5.00. Analysts at Ladenburg Thalmann raised their price target on shares of Antares Pharma from $5.00 to $5.75 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock.
Antares Pharma (NASDAQ:ATRS) traded up 3.53% on Monday, hitting $4.69. The stock had a trading volume of 12,560,788 shares. Antares Pharma has a 1-year low of $3.35 and a 1-year high of $4.72. The stock’s 50-day moving average is $4.29 and its 200-day moving average is $4.12. The company’s market cap is $596.4 million.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.03) by $0.01. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.82 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was up 28.9% on a year-over-year basis. On average, analysts predict that Antares Pharma will post $-0.15 earnings per share for the current fiscal year.
Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.